Saturday, November 14, 2026

One of world’s best gold mines now yields up to 10%

Dear Reader,

I’m a 30 year veteran gold analyst…

And today, I want to tell you about one of the world’s best gold mines.

This mine contains some of the highest grade ore found anywhere on the planet.

But that’s not even what excites me about this play…

Because this company has a very unique, high-yield dividend policy… Which is virtually unheard of in the mining industry.

And I’ve put all of the details together into a single report.

If you feel like you missed out on the early part of this bull market - this report is exactly what you need to get back on track.

Buy this security now and you can collect up to 10% yields AND get the upside of one of the world’s best gold mining operations.

Best,

Garrett Goggin, CFA, CMT
Lead Analyst and Founder, Golden Portfolio

P.S. The only catch: this security’s yield is already capturing the attention of global investors. Among them: the Rothschilds, Vanguard, and BlackRock. This is your chance to join them before it's too late.


 
 
 
 
 
 

Special Report

Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?

Author: Nathan Reiff. First Published: 11/10/2026.

Axon and Motorola Solutions logos split by candlestick stock charts, representing a comparison between the two companies.

Key Points

  • Axon Enterprise shares fell about 28% after an earnings per share miss and reduced free cash flow guidance, while Motorola Solutions stock rose roughly 7% on an earnings beat.
  • Motorola's results were driven by record orders, a nearly $17 billion backlog, and raised full-year guidance, while Axon faced delays to Dedrone counter-drone deployments and rising component costs.
  • Axon trades at a much higher valuation near 97 times earnings with greater analyst-estimated upside, while Motorola trades around 42 times earnings with less projected upside but more stability.
  • Special Report: Today's stock pick is on me tc pixel

Two big names in public safety technology reported earnings in early November 2026, but their paths diverged afterward.

Axon Enterprise (NASDAQ: AXON) plunged by around 28% in the days immediately following its Q3 2026 report, while Motorola Solutions Inc. (NYSE: MSI) climbed by roughly 7% over the same period. Motorola's performance was buoyed by an earnings beat, an increase to full-year guidance, and a record backlog.

Five tickers can still share one risk (Ad)

The vote ended. Your portfolio risks remain. Several tickers can share the same exposure. Explore our five-stock portfolio-resilience report, then compare the ideas with what you already own. Start the review before reacting to the next headline.

Let me see the reporttc pixel

At the same time, both companies are pursuing similar long-term goals, including potentially lucrative opportunities in the counter-drone space. As the year draws to a close, investors can use this latest financial check-in to assess whether Motorola may indeed be the safer bet or whether Axon's share price pullback has opened up an opportunity to buy.

Motorola's Earnings Beat Overshadows Axon's Growth

Axon's quarter may not have been as weak as the market's response suggests.

The company posted roughly 28% year-over-year (YOY) revenue growth to about $909 million, falling roughly $26 million short of expectations.

The bigger issue may have been that earnings per share fell 17 cents short of estimates.

Axon reduced its full-year free cash flow outlook to a range of $350 million to $400 million, down from its prior target of up to $450 million.

Additionally, the company expects delays to three significant Dedrone counter-drone deployments, which could push some revenue from these contracts into the next fiscal year. Higher memory and component costs are also weighing on margins.

On the bright side, Axon's software and services business grew, with revenue up a strong 43% YOY. Annual recurring revenue also surged by 40% YOY, while bookings rose considerably. The company's major investment in Skydio continues to bolster its reach into the drone market.

For Motorola, more modest revenue growth of 12% YOY still represented a substantial win over analyst expectations, with sales exceeding estimates by more than $112 million. Earnings per share (EPS) also came in 27 cents above estimates.

Motorola's strong performance rested in large part on record orders across many of its products, which helped produce a record-high backlog of almost $17 billion. In response, management raised its full-year revenue and EPS guidance, as well as its expectations for operating cash flow. The company's acquisitions of Silvus and D-Fend are already benefiting its overall revenue profile.

Axon's Growth Compared to Motorola's Profitability Advantage

The results from these two firms confirm that, by some measures, Axon is the faster-growing company. On the other hand, Motorola has stronger profitability metrics and may be more stable and predictable overall.

Still, it's not entirely clear which company may appeal more to investors.

The two operate in related but distinct spaces: Motorola is centered on mobile radios and command center software, while Axon focuses on cloud software, body cameras, TASER devices, and related products.

Axon faced challenges in its latest quarter, some of which were timing-related and others tied to external pressures, including tariffs on certain hardware products and higher memory and component costs. Delays in several major Dedrone deployments also pushed expected revenue into 2027.

Ultimately, both companies have demonstrated the strength of their products and the demand they can attract as a result.

Axon's Sell-Off Narrows the Valuation Gap—But Is It Enough?

Investors who see Axon's strong growth may view it as an attractive option despite its earnings miss. However, even after the recent sell-off, shares still trade at a hefty premium of almost 97x earnings. By contrast, Motorola stock trades at about 42x earnings.

Even after the price correction, Axon is far from a cheap stock. Its potential in the counter-drone space is significant, and that may still justify an investment for investors who are particularly bullish on the company's future opportunities.

Analysts are bullish on both names. Axon's Moderate Buy rating is based on 13 Buys and four Holds, and the stock also has almost 103% in predicted upside, a figure that is especially striking after the recent dip. Motorola, on the other hand, has even more optimistic ratings—a Buy overall based on 12 individual Buy ratings and a single Hold—but only about 4% in anticipated upside following its recent spike.

Both companies offer compelling reasons to invest, but Axon may face more turbulence, particularly if its revenue delays disrupt future earnings expectations. Motorola may trade some near-term appreciation potential for greater predictability.


Special Report

Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward

Author: Bridget Bennett. First Published: 11/13/2026.

Forget NVIDIA's Turmoil: 3 Stocks Where the Valuation Math Actually Works

Key Points

  • Ashland could unlock significant shareholder value through activist-driven strategic changes or a potential sale, although its turnaround remains unproven.
  • Central Garden & Pet offers strong cash flow and an attractive valuation, while a breakout above $45 could signal renewed investor confidence and upward momentum.
  • HCA Healthcare benefits from long-term demand for hospital services and earnings growth potential, but Medicaid funding cuts and health care policy uncertainty could pressure profitability.
  • Special Report: The Untold Story Behind Nvidia's CEO Bombshell tc pixel

The market's most important stock just lost its longtime leader. Jensen Huang has officially resigned from NVIDIA (NASDAQ: NVDA), with CFO Colette Kress stepping in as interim CEO.

The leadership shakeup has implications beyond NVIDIA shareholders. As a major holding in many broad-market and technology-focused exchange-traded funds (ETFs), a prolonged NVIDIA sell-off could weigh on the broader market.

Five tickers can still share one risk (Ad)

The vote ended. Your portfolio risks remain. Several tickers can share the same exposure. Explore our five-stock portfolio-resilience report, then compare the ideas with what you already own. Start the review before reacting to the next headline.

Let me see the reporttc pixel

But does the decline make NVIDIA a bargain? The stock was already about 30% below its highs before Huang's resignation. Marc Lichtenfeld, chief income strategist at The Oxford Club, believes NVIDIA's long-term growth story remains intact. At roughly 17x projected 2027 earnings, he considers the valuation reasonable, although waiting for the stock to stabilize could make sense.

The reflex is to buy the dip. But a falling share price doesn't necessarily mean a stock is undervalued. Lichtenfeld emphasizes business quality, cash flow and earnings growth relative to valuation rather than simply buying the dip.

For investors looking beyond NVIDIA's turmoil, Ashland (NYSE: ASH), Central Garden & Pet (NASDAQ: CENTA) and HCA Healthcare (NYSE: HCA) offer three very different investment opportunities, each with potential catalysts largely independent of the AI trade.

Ashland: Activist Campaign Could Unlock Hidden Value

Ashland makes additives and ingredients for food, beauty products, life sciences and other industries. The stock has been beaten up after years of uneven results.

The forward numbers look different.

Earnings are expected to grow 28% in the fiscal year ending September 2027 and another 32% over the next two years, yet shares trade at 18x 2027 earnings. That puts the price/earnings-to-growth (PEG) ratio well below one, suggesting the stock could be undervalued if those growth projections materialize.

But an earnings recovery isn't the only potential catalyst. Activist investors have also been pushing for changes that could unlock shareholder value. They've already added two board members, and the board is weighing strategic alternatives, which often means a sale or spin-off. A competitor sold a comparable materials business for 13x EBITDA. Applied to Ashland's guidance, that multiple implies a price of about $118 a share, roughly a 50% premium to the stock's price when Lichtenfeld ran the numbers. He doesn't expect a deal that rich, but the gap shows what could surface.

The risk is that the turnaround isn't proven yet, and 11% of the float is sold short by investors who usually do their homework. That positioning suggests significant skepticism about the company's prospects, but it could fuel a squeeze if the stock starts climbing and short sellers rush to cover. Upcoming quarterly earnings reports will help determine whether Ashland's recovery is gaining traction.

Central Garden & Pet: Cash Flow Faces a $45 Resistance Test

Central Garden & Pet offers a cleaner kind of cheap.

The roughly $2.6 billion company trades at about 14x forward earnings, below the sector median of 16, with earnings expected to grow 27% over the next four years.

Price-to-sales sits right around one, and price-to-cash-flow is just below eight, versus a sector median of 10.7. The company generates roughly $300 million a year in free cash flow, debt has held steady for years, and cash keeps building.

That financial stability is supported in part by Central Garden & Pet's exposure to relatively resilient consumer demand, particularly the humanization of pets. Owners treat dogs and cats as family, so in a downturn, they're more likely to trade down on food than give up the animal. That makes the business recession-resistant rather than recession-proof, according to Lichtenfeld.

Despite those financial strengths, Central Garden & Pet's stock has struggled to gain momentum. Shares peaked just below $45 in 2021 and have traded sideways since. In Lichtenfeld's view, a move above that level could put $60 within reach in about 12 months. Prices often move ahead of fundamentals as insiders and well-researched funds position early. The $45 line is the one to watch.

HCA Healthcare: Growth Outlook Faces a Medicaid Policy Test

HCA Healthcare runs the largest hospital network in the United States, with a significant presence in Texas and Florida. Population growth in both states, along with Florida's aging population, could help support long-term demand for hospital services.

The reality is that patients need care whether the economy is booming or contracting.

Earnings are projected to more than triple over the next 10 years, according to Lichtenfeld, yet the stock trades at a price-to-earnings (P/E) ratio of about 17 on both a trailing and forward basis, below the sector median of 20.

Estimates call for single-digit growth in 2026 and 2027, followed by double-digit growth every year from 2028 through 2035. Scale helps with cost control and local market dominance.

This isn't a bargain-bin rebound. Its shares have risen dramatically over the past 15 years and remain relatively close to their all-time high. But Lichtenfeld sees further potential in the company's ability to grow earnings over time, even without a deeply discounted valuation.

One of the biggest uncertainties surrounding HCA's long-term earnings outlook is federal health care policy. Changes to Medicaid funding and insurance coverage can affect both patient volumes and hospital reimbursement rates. HCA has already warned that it expects $550 million to $650 million less in Medicaid supplemental payment benefits in 2027, adding pressure to an already challenging reimbursement environment.

But politics cuts both ways. Democrats won control of both chambers in November and will take office in January 2027. Lichtenfeld sees potential upside if lawmakers move to reverse Medicaid cuts, although President Trump's veto power could limit their ability to enact major changes. A broader debate over Medicare for All could also resurface ahead of 2028, but its implications for hospitals would depend on the details of any proposal.

The upside is that health care policy turns slowly, like a cruise ship, so today's tailwinds could have legs.

Don't Chase the AI Dip: 3 Value Stocks, 3 Different Catalysts to Watch

Ashland, Central Garden & Pet and HCA Healthcare share one thread: Each pairs a credible growth outlook with a valuation that hasn't caught up, and none lives or dies on AI spending.

For Ashland, the opportunity hinges on a successful turnaround and the potential for activist-driven strategic changes. Central Garden & Pet needs to translate its steady cash flow into stronger share-price momentum, while HCA Healthcare must deliver sustained earnings growth amid ongoing uncertainty over health care policy.

When the market's biggest name is in flux, discipline matters more than the dip. Stay focused on earnings growth relative to price, because that's what moves undervalued stocks from overlooked to rewarded.

For monthly research on income and value ideas, join Marc Lichtenfeld's Oxford Income Letter for his latest stock picks.

Thank you for subscribing to The Early Bird, MarketBeat's 7:00 AM newsletter that covers stories that will impact the stock market each day.
 
This message is a paid sponsorship from Golden Portfolio, a third-party advertiser of The Early Bird and MarketBeat.
 
If you need assistance with your account, please email our support team, based in South Dakota, at contact@marketbeat.com.
 
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
 
Copyright 2006-2026 MarketBeat Media, LLC.
345 North Reid Place #620, Sioux Falls, SD 57103-7078. United States..
 
Just For You: After the midterms: question your stock shortlist tc pixel

No comments:

Page List

Blog Archive

Search This Blog

Iran War Shock: What I Was Told In That Private Meeting

It’s intentional. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏...